Global X China Biotech ETF

Risk Disclosures
Investors should not base on this document alone to make investment decisions. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

Global X China Biotech ETF (the “Fund”) investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.
Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly.
China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.
The trading price of the Unit on the SEHK is driven by market factors such as demand and supply of the Unit. Therefore, the Units may be traded at a substantial premium or discount to the Sub-Fund’s net asset value.

China Biotechnology:
Healthcare for
Tomorrow’s World

In A Single Trade,
Gain Access to 30 China Biotech Companies

Factsheet Brochure Product Details^#

2820 (HKD) / 9820 (USD)

Stock Code ( Read More )

China Biotech Index^

Underlying Index

HK$ ...

AUM¹ （---）

0.68%

Ongoing Charges
Over A Year²

2019/07/24

Inception Date

The only China
Biotech-Focused ETF

Listed on Stock Exchange
of Hong Kong³

“Most
Innovative ETF”

by The Asset Triple A
Sustainable Investing
Awards 2020⁴

Ranked no.2

among ETFs listed in Hong Kong in terms of performance since listing date^*

Return of Global X
China Biotech ETF^#

98.70%

Average Return of
ETFs in Hong Kong at
the same period^*

19.89%

Cumulative Performance (%)^#

3M%	1Yr%	3Yr%	5Yr%	YTD	Since Listing
7.21	69.7	N/A	N/A	69.7	98.70

Calendar Year Performance (%)^#

2020	2019	2018	2017	2016
69.7	17.09^	N/A	N/A	N/A

*Calculated by Mirae Asset Global Investments (Hong Kong) Limited based on figures from Bloomberg. The performance in this ranking from 25 July 2019 to 31 December 2020 is calculated by NAV to NAV basis in base currency and assumes dividend reinvestment for all the ETFs made available for Hong Kong investors. The Fund has been listed on Stock Exchange of Hong Kong since 25 July 2019. To ensure like with like comparisons, we have excluded suspended ETFs, delisted ETFs, ETFs launched after 25 July 2019, and leveraged and inverse products (L&I products) in our calculation. Moreover, as some ETFs’ (used as comparison) base currencies are not in RMB, the NAV of these ETFs may have fluctuated because of FX movements and it may not reflect actual performance of the underlying investments. This is for reference only and shall not be relied on as an investment advice. Moreover, past performance shall not be relied on for the future performance of the ETF. Source: Calculated with sources extracted from Bloomberg. As of 31 December 2020 . Click here to view full list.
# Calculated by Mirae Asset Global Investments (Hong Kong) Limited based on figures from Mirae Asset Global Investment. As of 31 December 2020. All performance numbers of the Fund are net of fees, NAV to NAV, in RMB. Where no past performance is shown there was insufficient data available in that year to provide performance. Past performance is not an indicator or a guarantee of future performance.
^Since listing date to end of calendar year.

THE CHINA BIOTECH INDEX^ HAS OUTPERFORMED VARIOUS MAJOR BROAD MARKET CHINA AND HONG KONG INDICES^%

The Index provides exposure to 30 Chinese companies that are active in the field of biotechnology.

Comparison between China Biotech^ and Various Major Broad Market China
and Hong Kong Indices^%

From 25 July 2019 to 31 December 2020

Comparison between China Biotech^ and Various Major Broad Market China and Hong Kong Indices^%

From 25 July 2019 to 31 December 2020

Why is Biotechnology Essential in China?

The United Nations (UN) forecasts that the size of the Chinese population with an age of 65 and above will double by 2050, from 176 million (12.6% of total) in 2019 to 366 million (26% of total) in 2050. This is well above the 7% threshold set by the UN to classify a society as an “aging society” and exceeds the global average of 9.1%.⁵

Chronic diseases such as strokes, cancer and respiratory and heart conditions have become the leading causes of deaths in China due to rising unhealthy lifestyle habits including more sedentary work, less exercise and poorer diets.

The 5 leading causes of years of life lost in China, 1990-2017

Rank

1

Stroke
2

Ischemic heart disease
3

Tracheal, bronchurs, and lung cancer
4

Chronic obstructive pulumonarydisease
5

Livercancer

China’s estimated cancer incidenceand mortality from 2012-2035

TOTAL NEW INCIDENCES

97% INCREASE

(YEAR)

TOTAL NEW DEATHS

80% INCREASE

(YEAR)

Benefits of
Biotechnological Therapies

Potential Applications of Biotechnology

Stem Cell

A future solution to treat brain diseases and blood diseases by regenerating organs & tissues and bone marrow transplants.

Genetic Diagnosis
and Gene Therapy

Detecting diseases that caused by inherited gene mutations and to cure the disease by altering genetic sequences.

Vaccines and
Cancer Treatment

Use of Biologics (Biological drugs) to activate own immune system, trigger the releases of killer cells to fight malfunctioning cells.

Advantages
of Biologics

Immunogenic Rapid, safe and
non-invasive Highly
Target-Specific Less Harmful
Non-Target
Effects Lower
Accumulation
in Tissues

Stem Cell

A future solution to treat brain diseases and blood diseases by regenerating organs & tissues and bone marrow transplants.

Genetic Diagnosis
and Gene Therapy

Detecting diseases that caused by inherited gene mutations and to cure the disease by altering genetic sequences.

Vaccines and
Cancer Treatment

Use of Biologics (Biological drugs) to activate own immune system, trigger the releases of killer cells to fight malfunctioning cells.

Advantages
of Biologics

Immunogenic

Rapid, safe and
non-invasive

Highly
Target-Specific

Less Harmful
Non-Target
Effects

Lower
Accumulation
in Tissues

Product Details

Discover More Investment
Themes in China

Subscribe Global X Updates

^ Underlying Index: Solactive China Biotech Index

Source: Mirae Asset Global Investment.
The ongoing charges figure is an annualized figure based on the expenses for the period from 1 April 2020 to 31 December 2020. It represents the sum of the ongoing expenses chargeable to the Sub-Fund for the above period expressed as a percentage of the Sub-Fund’s average Net Asset Value over the same period, annualized to give an ongoing charges figure over a year. This figure may vary from year to year.
Source: Hong Kong Stock Exchange. As of 30 October 2020.
Source: The Asset, June 2020.
Source: National Bureau of Statistics, 2020.
Source: South China Morning Post, October 2020.

This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for information purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments is the holding company of Mirae Asset Global Investments (Hong Kong) Limited with effective date 1 November 2019.

The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.

Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.

Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.

The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.

The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

COM-2020-11-19-HK-R-Web_2